FAK-IN-28

FAK-IN-28 is an orally active FAK inhibitor (IC50 = 0.4 nM) . FAK-IN-28 exhibits dual antiproliferative and anti-metastatic properties. FAK-IN-28 triggers caspase-3-dependent apoptosis via ROS elevation. FAK-IN-28 inhibits tumor growth without causing weight loss or hepatotoxicity. FAK-IN-28 is useful in the study of FAK-driven malignancies, such as colon cancer, cervical cancer, triple-negative breast cancer, and melanoma[1].

Product Specifications

UNSPSC

12352005

Target

Apoptosis; Caspase; FAK; Reactive Oxygen Species (ROS)

Related Pathways

Apoptosis; Immunology/Inflammation; Metabolic Enzyme/Protease; NF-κB; Protein Tyrosine Kinase/RTK

Field of Research

Cancer

Smiles

COC1=CC(N2CCN(C(C3=CC=CC(S(=O)(N4CCN(C(C)=O)CC4)=O)=C3)=O)CC2)=CC=C1NC5=NC(NC6=C(C(NC)=O)C=CC=C6)=C(C(F)(F)F)C=N5

Molecular Formula

C37H40F3N9O6S

Molecular Weight

795.83

References & Citations

[1]Gong L, et al. Molecular hybridization-driven FAK inhibitors: N-2,4-diarylaminopyrimidine-3-sulfamoyl-benzamide derivatives with improved antitumor potency. Eur J Med Chem. 2025 Oct 15;296:117885.